Literature DB >> 17611572

Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia.

L Shvidel, E Sigler, M Haran, A Klepfish, A Duek, A Berrebi, M Shtalrid.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17611572     DOI： 10.1038/sj.leu.2404743

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

Review 1.  Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.

Authors:  Bethany Samuelson; Chatree Chai-Adisaksopha; David Garcia
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

Review 2.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2019-01-24       Impact factor: 10.047

Review 3.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-03       Impact factor: 10.047

4.  Essential thrombocythemia: Busulphan revisited.

Authors:  Prasad R Koduri
Journal:  Indian J Med Paediatr Oncol       Date:  2016 Apr-Jun

Review 5.  Essential thrombocythemia treatment algorithm 2018.

Authors:  Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-01-10       Impact factor: 11.037

Review 6.  MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.

Authors:  Julian Grabek; Jasmin Straube; Megan Bywater; Steven W Lane
Journal:  Cells       Date:  2020-08-14       Impact factor: 6.600

7.  Ruxolitinib for the Treatment of Essential Thrombocythemia.

Authors:  Arief Gunawan; Patrick Harrington; Natalia Garcia-Curto; Donal McLornan; Deepti Radia; Claire Harrison
Journal:  Hemasphere       Date:  2018-06-12

8.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037

9.  Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms.

Authors:  Michal Bar-Natan; Ronald Hoffman
Journal:  Expert Rev Hematol       Date:  2020-10-19       Impact factor: 2.929
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.